

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
SCOPE OF REPORT .....	1
INTENDED AUDIENCE.....	2
ANALYST CREDENTIALS.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
RELATED REPORTS .....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER .....	5
 CHAPTER TWO: SUMMARY.....	 6
<i>SUMMARY TABLE GLOBAL BIOMARKERS FORECAST BY AREA,</i> <i>THROUGH 2015 (\$ MILLIONS).....</i>	 6
<i>SUMMARY FIGURE GLOBAL BIOMARKERS FORECAST BY AREA,</i> <i>THROUGH 2015 (\$ MILLIONS).....</i>	 7
SUMMARY (CONTINUED) .....	8
 CHAPTER THREE: OVERVIEW .....	 9
INTRODUCTION .....	9
<i>TABLE 1 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 (\$</i> <i>MILLIONS).....</i>	 10
ENABLING ADVANCEMENTS DRIVING MARKET GROWTH .....	10
BIOMARKERS DRIVE SPEED, COST AND QUALITY	
IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT	
SPECTRUM .....	10
COST REDUCTION OPPORTUNITIES ARISING FROM	
BIOMARKER APPLICATIONS.....	11
Elements of Cost in Drug Research & Development .....	12
<i>FIGURE 1 CUMULATIVE COST OF CLINICAL DRUG</i> <i>DEVELOPMENT.....</i>	 13
<i>FIGURE 2 AVOIDABLE COST OF \$177.4B OF DRUG-RELATED</i> <i>MORBIDITY AND MORTALITY.....</i>	 14
Elements of Cost in Healthcare .....	15
<i>FIGURE 3 VARIANCE ANALYSIS OF INCREASED COST</i> <i>ORIGINATING FROM DRUG-RELATED MORBIDITY AND</i> <i>MORTALITY.....</i>	 15
STRATEGIC BIOMARKER APPLICATIONS.....	16
Targeted Therapies.....	16
Product Extensions.....	17
Ultra-Blockbuster .....	18
DRUG DEVELOPMENT USING BIOMARKERS: MARKET	
ENTRY THEORY AND IMPLICATIONS .....	19

<i>FIGURE 4 DECISION TREE AND ECONOMICS FOR BIOMARKERS</i>	
<i>AT POINT OF CARE</i> .....	20
Breakeven Analysis of Diagnostic-Enabled Drug Model .....	20
<i>FIGURE 5 PRICE, COST, ADOPTION PERCENT FOR BIOMARKER</i>	
<i>ENVIRONMENT</i> .....	21
<i>FIGURE 6 BREAKEVEN LEVEL FOR ADOPTION OF BIOMARKER</i> .....	22
Implications for Industry .....	22
BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT.....	23
Safety/toxicology Biomarkers.....	23
<i>TABLE 2 NOVEL SAFETY / TOXICOLOGY BIOMARKERS USED IN</i>	
<i>CANCER, CARDIO AND RENAL</i> .....	24
Dose Selection and Dose Optimization .....	24
<i>TABLE 3 NOVEL DOSE SELECTION BIOMARKERS USED IN</i>	
<i>CANCER, DIABETES, METABOLIC AND LIVER DISEASE</i> .....	25
Improved Measurement of Therapeutic Efficacy .....	25
Outcome Biomarkers and Surrogate Endpoints .....	26
<i>TABLE 4 PATIENT OUTCOME MEASUREMENTS BIOMARKERS</i> .....	26
EARLY-STAGE CLINICAL TRIAL APPLICATIONS .....	26
LATE-STAGE CLINICAL TRIAL APPLICATIONS .....	27
Phase III.....	27
Phase IV.....	27
BIOMARKERS: CHALLENGES AND OPPORTUNITIES .....	28
SUMMARY .....	28
CLINICAL VALIDITY: REQUIREMENTS .....	28
BIOMARKER OPPORTUNITIES .....	28
PRODUCT SUMMARY AND MARKET.....	28
GENOMICS .....	28
<i>TABLE 5 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 (\$</i>	
<i>MILLIONS)</i> .....	29
IMAGING .....	29
PROTEOMICS.....	30
BIOINFORMATICS .....	30
OTHER .....	31
Metabolomics .....	31
BIOMARKER ADOPTION BY THE PHARMACEUTICAL	
INDUSTRY.....	31
GROWTH DRIVERS AND RESISTORS .....	32
FACTORS INFLUENCING BIOMARKER ADOPTION IN	
CLINICAL TRIALS .....	32
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE.....	32
IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL	
TRIALS.....	32
Merck: Vicriviroc.....	33
Myriad: Flurizan.....	33

ADDITIONAL CAPABILITIES BY LARGE SERVICE PLAYERS .....	33
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND PROTEOMICS .....	34
BIOMARKER MARKET FORECAST.....	34
<i>TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i> .....	34
CHAPTER FOUR REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS .....	35
INTRODUCTION .....	35
ROLE OF THE FOOD AND DRUG ADMINISTRATION .....	35
<i>TABLE 7 FDA GUIDELINES FOR BIOMARKER APPLICATIONS</i> .....	36
EUROPEAN MEDICINES AGENCY .....	37
REGULATORY IMPACT ON DRUG SAFETY .....	38
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING .....	38
APPROVED PATENT ANALYSIS.....	38
<i>TABLE 8 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN U.S., EUROPE, JAPAN, THROUGH 2010</i> .....	38
COMPETITIVE LANDSCAPE .....	39
LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING.....	39
<i>TABLE 9 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2010 (\$ MILLIONS)</i> .....	39
<i>TABLE 10 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY</i> .....	40
<i>TABLE 10 (CONTINUED)</i> .....	41
<i>TABLE 11 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN U.S., EUROPE, JAPAN</i> .....	41
<i>TABLE 11 (CONTINUED)</i> .....	42
<i>TABLE 11 (CONTINUED)</i> .....	43
ETHICAL CONSIDERATIONS .....	43
SUMMARY .....	43
Summary (Continued) .....	44
Respect for Persons.....	45
Beneficence .....	45
Justice .....	46
BIOMARKER APPLICATIONS OF ETHICAL CONSIDERATIONS .....	46
Race and Genotype .....	46
Negligence.....	47
Informed Consent .....	47
Privacy .....	48
Market Segmentation.....	49

Professional, Media, and Opinion Leader Edification .....	49
REGULATORY IMPLICATIONS.....	50
CHAPTER FIVE: APPLICATION BY THERAPY AREA.....	51
<i>TABLE 12 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS     BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS)</i> .....	51
ONCOLOGY.....	51
<i>TABLE 13 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:</i>	
ONCOLOGY.....	52
COLORECTAL CANCER.....	52
CETUXIMAB.....	52
Cetuximab (Continued).....	53
Cetuximab (Continued).....	54
PANITUMUMAB.....	55
Panitumumab (Continued).....	56
ELESCLOMOL.....	57
HERCEPTIN.....	58
OTHER PREDICTIVE TESTS.....	58
<i>TABLE 14 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
ONGOING: ONCOLOGY.....	59
BREAST CANCER.....	60
MAMMAPRINT.....	60
<i>TABLE 15 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
ONGOING: BREAST CANCER.....	61
<i>TABLE 15 (CONTINUED)</i> .....	62
ONCOTYPE DX.....	62
TEST ADOPTION.....	63
Test Adoption (Continued).....	64
Test Adoption (Continued).....	65
OTHER PROGNOSTIC TESTS.....	66
Other Prognostic Tests (Continued).....	67
PREDICTIVE TESTS.....	68
HORMONAL THERAPIES.....	68
Hormonal Therapies (Continued).....	69
Hormonal Therapies (Continued).....	70
TAXANES/ANTHRACYCLINES.....	71
Hormonal Therapies (Continued).....	72
BIOLOGICALS.....	73
TRIPLE NEGATIVE BREAST CANCER.....	74
Triple Negative Breast Cancer (Continued).....	75
OTHER NOVEL BIOMARKERS.....	76
LUNG CANCER.....	77
INTRODUCTION.....	77
PREDICTIVE TESTS.....	77

<i>TABLE 16 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
ONGOING: LUNG CANCER .....	77
<i>TABLE 16 (CONTINUED)</i> .....	78
GEFITINIB.....	78
Gefitinib (Continued).....	79
ERLOTINIB.....	80
OTHER PREDICTIVE TESTS .....	81
NOVEL THERAPIES.....	82
OTHER ONCOLOGY.....	83
PROSTATE CANCER .....	83
Prostate Cancer (Continued).....	84
OVARIAN CANCER .....	85
MALIGNANT MELANOMA.....	86
<i>TABLE 17 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
ONGOING: MALIGNANT MELANOMA .....	86
OTHER DISEASES .....	87
CARDIOVASCULAR .....	87
<i>TABLE 18 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
ONGOING: CARDIOVASCULAR.....	87
Cardiovascular (Continued) .....	88
<i>TABLE 19 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:</i>	
CARDIOVASCULAR .....	89
CENTRAL NERVOUS SYSTEM.....	90
<i>TABLE 20 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:</i>	
CNS DISEASE.....	91
<i>TABLE 20 (CONTINUED)</i> .....	92
<i>TABLE 21 CLINICAL BIOMARKERS IN CYP2D6 FAMILY FOR CNS</i>	
DISEASE.....	92
IMMUNOLOGY .....	92
<i>TABLE 22 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:</i>	
IMMUNOLOGY.....	93
Immunology: Benlysta: Human Genome Sciences.....	93
Expedition & Identity Alzheimer’s trial: Eli Lilly.....	93
CLINICAL BIOMARKERS: THERAPEUTIC DISEASE MARKET	
FORECAST .....	94
<i>TABLE 23 GLOBAL MARKET FORECAST FOR CLINICAL STAGE</i>	
BIOMARKERS, THROUGH 2015 (\$ MILLIONS).....	94
<i>TABLE 24 2015 GLOBAL MARKET FORECAST OF BIOMARKERS IN</i>	
LATE STAGE CLINICAL USE BY THERAPEUTIC AREA,	
THROUGH 2015 (\$ MILLIONS).....	94
<i>TABLE 25 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE</i>	
STAGE CLINICAL USE BY REGION, THROUGH 2015 (\$ MILLIONS).....	94
 CHAPTER SIX: BIOMARKERS ACTIVELY GUIDING DRUG	
DEVELOPMENT .....	95

INTRODUCTION .....	95
<i>TABLE 26 RECENT CORPORATE ALLIANCES BETWEEN</i>	
<i>BIOMARKER AND DRUG DEVELOPMENT COMPANIES.....</i>	<i>95</i>
ASURAGEN .....	96
BACKGROUND .....	96
COLLABORATION: MERCK & CO.....	96
BG MEDICINE .....	96
BACKGROUND .....	96
COLLABORATION: CORDEX PHARMA.....	96
BIOMÉRIEUX.....	97
BACKGROUND .....	97
COLLABORATIONS: ISPEN; MERCK & CO.....	97
Ipsen.....	97
Merck & Co.....	97
ADNA PROJECT.....	98
CELERA .....	98
BACKGROUND .....	98
COLLABORATIONS.....	99
Abbott.....	99
Merck & Co .....	99
Ipsen.....	99
CURIDIUM .....	100
BACKGROUND .....	100
COLLABORATION: TAKEDA .....	100
DAKO .....	100
BACKGROUND .....	100
COLLABORATION: OSI .....	100
OSI Pharmaceuticals.....	101
Genentech .....	101
Bristol-Myers Squibb.....	101
DXS.....	101
BACKGROUND .....	101
COLLABORATIONS.....	102
Amgen .....	102
Roche Molecular Diagnostics .....	102
GE HEALTHCARE.....	103
BACKGROUND .....	103
COLLABORATION: ELI LILLY .....	103
GENOMIC HEALTH .....	103
BACKGROUND .....	103
COLLABORATIONS.....	103
Pfizer .....	104
Bristol-Myers Squibb and ImClone Systems.....	104
HISTORX .....	104

BACKGROUND .....	104
COLLABORATION: LILLY .....	105
LILLY.....	105
LABCORP.....	105
BACKGROUND .....	105
COLLABORATION.....	105
ARCA Biopharma .....	106
Vanda Pharmaceuticals .....	106
Medco Health Solutions .....	107
MONOGRAM BIOSCIENCES .....	107
BACKGROUND .....	107
COLLABORATIONS.....	107
Pfizer HIV Partnership .....	107
VeraTag Oncology Platform .....	108
ONCOMETHYLOME SCIENCES .....	108
BACKGROUND .....	108
COLLABORATIONS.....	108
Merck KGaA .....	109
Schering-Plough.....	109
GlaxoSmithKline Biologicals .....	109
Abbott.....	109
SOURCE MDX.....	109
BACKGROUND .....	109
COLLABORATION: PFIZER .....	109
XDX.....	110
BACKGROUND .....	110
COLLABORATION: BRISTOL-MYERS SQUIBB.....	110
CHAPTER SEVEN: COMPANY ANALYSIS .....	111
<i>TABLE 27 PRINCIPAL FOCUS OF BIOMARKERS:</i>	
<i>PHARMACEUTICAL COMPANIES BY THERAPEUTIC AREA.....</i>	<i>111</i>
ABBOTT LABORATORIES INC.....	111
COMPANY OVERVIEW.....	111
PRODUCTS AND SERVICES.....	112
<i>TABLE 28 ABBOTT REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS .....</i>	<i>112</i>
COMPANY STRATEGY.....	112
AFFYMETRIX, INC.....	113
COMPANY OVERVIEW.....	113
PRODUCTS AND SERVICES.....	113
COMPANY STRATEGY.....	113
ASTELLAS PHARMA INC.....	114
COMPANY OVERVIEW.....	114
PRODUCTS AND SERVICES.....	114
COMPANY STRATEGY.....	114

ASTRAZENECA LTD .....	115
COMPANY OVERVIEW .....	115
PRODUCTS AND SERVICES .....	115
<i>TABLE 29 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i> .....	<i>116</i>
COMPANY STRATEGY.....	116
BANYAN BIOMARKERS, INC.....	116
COMPANY OVERVIEW .....	116
PRODUCTS AND SERVICES .....	117
COMPANY STRATEGY.....	117
BAYER SCHERING PHARMA AG.....	117
COMPANY OVERVIEW .....	117
PRODUCTS AND SERVICES .....	117
COMPANY STRATEGY.....	118
BG MEDICINE, INC. ....	118
COMPANY OVERVIEW.....	118
PRODUCTS AND SERVICES .....	119
COMPANY STRATEGY.....	119
BIOPHYSICAL CORP .....	120
COMPANY OVERVIEW .....	120
PRODUCTS AND SERVICES .....	120
COMPANY STRATEGY.....	120
BIOSYSTEMS INTERNATIONAL INC .....	121
COMPANY OVERVIEW .....	121
PRODUCTS AND SERVICES .....	121
COMPANY STRATEGY.....	121
BOEHRINGER INGELHEIM GMBH .....	122
COMPANY OVERVIEW .....	122
PRODUCTS AND SERVICES .....	122
COMPANY STRATEGY.....	122
BRISTOL-MYERS SQUIBB CO.....	123
COMPANY OVERVIEW .....	123
PRODUCTS AND SERVICES .....	123
<i>TABLE 30 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING</i>	
<i>BIOMARKERS</i> .....	<i>123</i>
COMPANY STRATEGY.....	124
CAPRION PROTEOMICS INC .....	124
COMPANY OVERVIEW .....	124
PRODUCTS AND SERVICES .....	124
COMPANY STRATEGY.....	124
CLINICAL DATA, INC.....	125
COMPANY OVERVIEW .....	125
PRODUCTS AND SERVICES .....	125
COMPANY STRATEGY.....	126



CORRELOGIC SYSTEMS, INC.....	126
COMPANY OVERVIEW.....	126
PRODUCTS AND SERVICES.....	126
COMPANY STRATEGY.....	127
DAIICHI SANKYO COMPANY, LTD.....	127
COMPANY OVERVIEW.....	127
PRODUCTS AND SERVICES.....	127
COMPANY STRATEGY.....	128
EISAI CO. LTD. ....	128
COMPANY OVERVIEW.....	128
PRODUCTS AND SERVICES.....	129
COMPANY STRATEGY.....	129
ELI LILLY AND COMPANY .....	129
COMPANY OVERVIEW.....	129
PRODUCT AND SERVICES .....	130
<i>TABLE 31 ELI LILLY REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS .....</i>	<i>130</i>
COMPANY STRATEGY.....	130
EPIGENOMICS AG.....	131
COMPANY OVERVIEW.....	131
PRODUCTS AND SERVICES.....	131
COMPANY STRATEGY.....	131
GENEDATA AG.....	132
COMPANY OVERVIEW.....	132
PRODUCTS AND SERVICES.....	132
COMPANY STRATEGY.....	133
GENEGO, INC.....	133
COMPANY OVERVIEW.....	133
PRODUCTS AND SERVICES.....	133
COMPANY STRATEGY.....	134
GENENEWS LTD.....	134
COMPANY OVERVIEW.....	134
PRODUCTS AND SERVICES.....	135
COMPANY STRATEGY.....	135
GLAXOSMITHKLINE.....	135
COMPANY OVERVIEW.....	135
PRODUCTS AND SERVICES.....	136
<i>TABLE 32 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING</i>	
<i>BIOMARKERS.....</i>	<i>136</i>
COMPANY STRATEGY.....	136
JOHNSON & JOHNSON LTD.....	137
COMPANY OVERVIEW.....	137
PRODUCTS AND SERVICES.....	137
COMPANY STRATEGY.....	138

MERCK & CO. ....	138
COMPANY OVERVIEW .....	138
PRODUCTS AND SERVICES .....	138
<i>TABLE 33 MERCK REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i> .....	139
COMPANY STRATEGY.....	139
NOVARTIS AG .....	140
COMPANY OVERVIEW .....	140
PRODUCTS AND SERVICES .....	140
<i>TABLE 34 NOVARTIS REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i> .....	140
COMPANY STRATEGY.....	141
PFIZER INC.....	141
COMPANY OVERVIEW .....	141
PRODUCTS AND SERVICES .....	141
<i>TABLE 35 PFIZER REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i> .....	142
COMPANY STRATEGY.....	142
ROCHE LTD .....	142
COMPANY OVERVIEW .....	142
PRODUCTS AND SERVICES .....	143
<i>TABLE 36 ROCHE REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i> .....	143
COMPANY STRATEGY.....	143
SANOFI-AVENTIS .....	144
COMPANY OVERVIEW .....	144
PRODUCTS AND SERVICES .....	144
<i>TABLE 37 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i> .....	145
COMPANY STRATEGY.....	145
TAKEDA PHARMACEUTICALS LTD .....	146
COMPANY OVERVIEW .....	146
PRODUCTS AND SERVICES .....	146
COMPANY STRATEGY.....	146
TEVA PHARMACEUTICAL INDUSTRIES LTD. ....	147
COMPANY OVERVIEW .....	147
PRODUCTS AND SERVICES .....	147
COMPANY STRATEGY.....	148